Experiences of Participation in a Multimodal Preventive Trial MIND-AD

Alzheimer’s disease multimodal prevention participation qualitative method

Journal

Journal of multidisciplinary healthcare
ISSN: 1178-2390
Titre abrégé: J Multidiscip Healthc
Pays: New Zealand
ID NLM: 101512691

Informations de publication

Date de publication:
2022
Historique:
received: 03 11 2021
accepted: 10 12 2021
entrez: 7 2 2022
pubmed: 8 2 2022
medline: 8 2 2022
Statut: epublish

Résumé

Alzheimer's disease (AD) is one of the world's leading public health challenges. One-third of AD cases are attributable to modifiable vascular and lifestyle-related risk factors. The Multimodal Preventive Trial for Alzheimer's Disease, MIND-AD The study aimed to explore and describe the experiences of participation in MIND-AD This qualitative study was part of the larger MIND-AD The results are presented as categories of (i) knowledge of AD and prevention, (ii) motives for study participation, (iii) experiences of the received information about the study, (iv) taking the decision to participate, (v) expectations on study participation, (vi) experiences of study participation and (vii) internal and external factors influencing study participation. The MIND-AD

Identifiants

pubmed: 35125872
doi: 10.2147/JMDH.S345607
pii: 345607
pmc: PMC8811792
doi:

Types de publication

Journal Article

Langues

eng

Pagination

219-234

Informations de copyright

© 2022 Akenine et al.

Déclaration de conflit d'intérêts

Miia Kivipelto reports Advisory boards: Combinostics, Swedish Care International, Roche, Biogen Board of Governors member: Alzheimer’s Drug Discovery Foundation Guidelines development group: WHO Governance Committee member: Global Council on Brain Health Grant support: Academy of Finland, Swedish Research Council, Social Insurance Institution of Finland, Ministry of Education and Culture of Finland, Alzheimer’s Research and Prevention Foundation, EU 7th framework, AXA Research Foundation, CIMED, JPND, IMI, EiT-Health, Wallenberg Clinical grant, Stiftelse Stockholms Sjukhem, FORTE, KI-Janssen Strategic Collaboration, Imperial College ITMAT, Gates Ventures/ADDI, Alzheimer’s Drug Discovery Foundation, Part the Cloud. No other conflict of interest in this study is reported by the authors.

Références

Lancet. 2015 Jun 6;385(9984):2255-63
pubmed: 25771249
BMJ Open. 2020 Aug 6;10(8):e037050
pubmed: 32764085
Alzheimers Dement. 2013 May;9(3):356-359.e1
pubmed: 23141383
Int Psychogeriatr. 2014 Oct;26(10):1649-57
pubmed: 24990196
Alzheimers Dement. 2011 Jul;7(4):e109-17
pubmed: 21784343
Sociol Health Illn. 2018 Jul;40(6):969-987
pubmed: 29659032
Alzheimer Dis Assoc Disord. 2019 Oct-Dec;33(4):299-306
pubmed: 31567302
J Patient Exp. 2020 Feb;7(1):124-131
pubmed: 32128381
Continuum (Minneap Minn). 2016 Apr;22(2 Dementia):419-34
pubmed: 27042902
Lancet. 2016 Aug 20;388(10046):797-805
pubmed: 27474376
Curr Alzheimer Res. 2012 Dec;9(10):1126-34
pubmed: 22631442
Dementia (London). 2016 May 13;:
pubmed: 27179001
Aging Clin Exp Res. 2018 Feb;30(2):209-212
pubmed: 28523610
Ann Neurol. 2008 Nov;64(5):492-8
pubmed: 19067364
Pilot Feasibility Stud. 2021 Jan 4;7(1):3
pubmed: 33390187
Alzheimers Dement. 2016 Jan;12(1):60-4
pubmed: 26710325
Neurology. 2011 Jan 18;76(3):280-6
pubmed: 21178097
Sci Transl Med. 2011 Nov 30;3(111):111cm33
pubmed: 22133718
J Alzheimers Dis. 2018;64(1):71-78
pubmed: 29865075
Int Psychogeriatr. 2011 Sep;23(7):1026-43
pubmed: 21281553
BMC Geriatr. 2020 Mar 12;20(1):99
pubmed: 32164544
J Prev Alzheimers Dis. 2017;4(2):125-131
pubmed: 29186282
Nurs Stand. 2008 Feb 13-19;22(23):35-40
pubmed: 18323051
JAMA Neurol. 2014 Aug;71(8):961-70
pubmed: 24886908
BMJ Open. 2019 Jun 6;9(6):e023480
pubmed: 31175194
J Adv Nurs. 2015 Jul;71(7):1694-703
pubmed: 25702823
Lancet Neurol. 2011 Sep;10(9):819-28
pubmed: 21775213
Alzheimer Dis Assoc Disord. 2014 Jan-Mar;28(1):1-8
pubmed: 24322484
PLoS One. 2019 Jul 10;14(7):e0219541
pubmed: 31291337
Nurse Educ Today. 2017 Sep;56:29-34
pubmed: 28651100
Alzheimers Res Ther. 2017 Oct 4;9(1):81
pubmed: 28978335
Lancet Neurol. 2014 Jun;13(6):614-29
pubmed: 24849862
Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):255-75
pubmed: 26207322
Clin Nurs Res. 2018 Feb;27(2):191-212
pubmed: 29374986
J Alzheimers Dis. 2019;69(4):1067-1075
pubmed: 31156168
Lancet. 2017 Dec 16;390(10113):2673-2734
pubmed: 28735855
J Am Med Dir Assoc. 2019 Jul;20(7):843-849.e5
pubmed: 30541689
Nurse Educ Today. 2004 Feb;24(2):105-12
pubmed: 14769454
Gerontologist. 2020 May 15;60(4):693-703
pubmed: 31322657
Lancet Neurol. 2017 May;16(5):377-389
pubmed: 28359749
Age Ageing. 2017 Sep 1;46(5):865-869
pubmed: 28531240
Trials. 2018 Sep 29;19(1):528
pubmed: 30268150

Auteurs

Ulrika Akenine (U)

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.

Charlotta Thunborg (C)

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
School of Health, Care and Social Welfare, Department of Physiotherapy, Mälardalen University, Västerås, Sweden.

Miia Kivipelto (M)

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
School of Health, Care and Social Welfare, Department of Physiotherapy, Mälardalen University, Västerås, Sweden.
Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
Stockholms Sjukhem, Research & Development Unit, Stockholm, Sweden.

Mandana Fallahpour (M)

Department of Neurobiology, Care Sciences and Society, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
Department of Neurobiology, Care Sciences and Society, Division of Occupational Therapy, Karolinska Institutet, Stockholm, Sweden.

Classifications MeSH